Show simple item record

dc.contributor.authorHojabri, Z
dc.contributor.authorRezaee, MA
dc.contributor.authorNahaei, MR
dc.contributor.authorSoroush, MH
dc.contributor.authorGhojazadeh, M
dc.contributor.authorPirzadeh, T
dc.contributor.authorDavodi, M
dc.contributor.authorGhazi, M
dc.contributor.authorBigverdi, R
dc.contributor.authorPajand, O
dc.contributor.authorAghazadeh, M
dc.date.accessioned2018-08-26T08:50:56Z
dc.date.available2018-08-26T08:50:56Z
dc.date.issued2013
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/53151
dc.description.abstractPurpose: The antimicrobial activity of doripenem in comparison of imipenem, meropenem and ertapenem among Pseudomonas aeruginosa isolated from burn and Cystic Fibrosis (CF) patients were determined. Methods: Metallo-?-lactamase (MBL) genes in imipenem non susceptible P. aeruginosa isolates were detected using PCR method. The in vitro susceptibilities of doripenem, imipenem, meropenem and ertapenem were determined by Etests. MIC50 and MIC90 for corresponding antibiotics were determined individually in burn and CF isolates. Results: Among isolates which were resistant to imipenem, 16 isolates were positive for the bla IMP gene. All isolates had no bla VIM gene. All MBL producing isolates were excluded. MIC50/MIC90 of doripenem in CF and burn isolates were 0.75/>32 and >32/>32 mg/L respectively. The corresponding values for imipenem in CF and burn isolates were 2/>32 and >32/>32 mg/L, respectively. Conclusion: The susceptibility rate of doripenem is higher than that of imipenem and meropenem among P.aeruginosa isolated from CF patients, whereas, there is no difference between the efficiency of doripenem and old carbapenems in non MBL producing P.aeruginosa isolates in burn patients. آ© 2013 by Tabriz University of Medical Sciences.
dc.language.isoEnglish
dc.relation.ispartofAdvanced Pharmaceutical Bulletin
dc.subjectamikacin
dc.subjectaztreonam
dc.subjectcarbapenem derivative
dc.subjectcefepime
dc.subjectceftazidime
dc.subjectciprofloxacin
dc.subjectdoripenem
dc.subjectertapenem
dc.subjectgentamicin
dc.subjectimipenem
dc.subjectmeropenem
dc.subjectmetallo beta lactamase
dc.subjectpiperacillin plus tazobactam
dc.subjectticarcillin
dc.subjecttobramycin
dc.subjecttrimethoprim
dc.subjectantibacterial activity
dc.subjectantibiotic sensitivity
dc.subjectarticle
dc.subjectbacterium detection
dc.subjectbacterium isolation
dc.subjectburn
dc.subjectcomparative effectiveness
dc.subjectcontrolled study
dc.subjectcystic fibrosis
dc.subjectdrug screening
dc.subjectgene
dc.subjecthuman
dc.subjectin vitro study
dc.subjectmajor clinical study
dc.subjectmetallo beta lactamase gene
dc.subjectminimum inhibitory concentration
dc.subjectnonhuman
dc.subjectpolymerase chain reaction
dc.subjectPseudomonas aeruginosa
dc.titleComparison of in vitro activity of doripenem versus old carbapenems against pseudomonas aeruginosa clinical isolates from both CF and burn patients
dc.typeArticle
dc.citation.volume3
dc.citation.issue1
dc.citation.spage121
dc.citation.epage125
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.5681/apb.2013.020


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record